MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

Lev Demidov (1) , John A. Thompson , Igor Bondarenko , Jaroslaw Jaroszek , Susana Puig , Gabriela Cinat , Axel Hauschild , Jelle J. Goeman , Hans C. Van Houwelingen , Fernando Ulloa-Montoya , Andrea Callegaro , Benjamin Dizier , Bart Spiessens , Muriel Debois , Vincent G. Brichard , Jamila Louahed , Patrick Therasse , Channa Debruyne , John M. Kirkwood , Brigitte Dreno (2) , John F. Thompson , Bernard Mark Smithers , Mario Santinami , Thomas Jouary , Ralf Gutzmer , Evgeny Levchenko , Piotr Rutkowski , Jean-Jacques Grob (3) , Sergii Korovin , Kamil Drucis , Florent Grange , Laurent Machet , Peter Hersey , Ivana Krajsova , Alessandro Testori , Robert Conry , Bernard Guillot (4, 5) , Wim H. J. Kruit

1 Russian Cancer Research Centre
2 UN - Université de Nantes
3 TIMONE - Hôpital de la Timone [CHU - APHM]
4 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
5 Pathogénèse et contrôle des infections chroniques (PCCI)

BACKGROUND: Despite newly approved treatments, metastatic melanoma remains a life-threatening condition. We aimed to evaluate the efficacy of the MAGE-A3 immunotherapeutic in patients with stage IIIB or IIIC melanoma in the adjuvant setting. METHODS: DERMA was a phase 3, double-blind, randomised, placebo-controlled trial done in 31 countries and 263 centres. Eligible patients were 18 years or older and had histologically proven, completely resected, stage IIIB or IIIC, MAGE-A3-positive cutaneous melanoma with macroscopic lymph node involvement and an Eastern Cooperative Oncology Group performance score of 0 or 1. Randomisation and treatment allocation at the investigator sites were done centrally via the internet. We randomly assigned patients (2:1) to receive up to 13 intramuscular injections of recombinant MAGE-A3 with AS15 immunostimulant (MAGE-A3 immunotherapeutic; 300 μg MAGE-A3 antigen plus 420 μg CpG 7909 reconstituted in AS01B to a total volume of 0\textperiodcentered5 mL), or placebo, over a 27-month period: five doses at 3-weekly intervals, followed by eight doses at 12-weekly intervals. The co-primary outcomes were disease-free survival in the overall population and in patients with a potentially predictive gene signature (GS-positive) identified previously and validated here via an adaptive signature design. The final analyses included all patients who had received at least one dose of study treatment; analyses for efficacy were in the as-randomised population and for safety were in the as-treated population. This trial is registered with ClinicalTrials.gov, number NCT00796445. FINDINGS: Between Dec 1, 2008, and Sept 19, 2011, 3914 patients were screened, 1391 randomly assigned, and 1345 started treatment (n=895 for MAGE-A3 and n=450 for placebo). At final analysis (data cutoff May 23, 2013), median follow-up was 28\textperiodcentered0 months [IQR 23\textperiodcentered3-35\textperiodcentered5] in the MAGE-A3 group and 28\textperiodcentered1 months [23\textperiodcentered7-36\textperiodcentered9] in the placebo group. Median disease-free survival was 11\textperiodcentered0 months (95% CI 10\textperiodcentered0-11\textperiodcentered9) in the MAGE-A3 group and 11\textperiodcentered2 months (8\textperiodcentered6-14\textperiodcentered1) in the placebo group (hazard ratio [HR] 1\textperiodcentered01, 0\textperiodcentered88-1\textperiodcentered17, p=0\textperiodcentered86). In the GS-positive population, median disease-free survival was 9\textperiodcentered9 months (95% CI 5\textperiodcentered7-17\textperiodcentered6) in the MAGE-A3 group and 11\textperiodcentered6 months (5\textperiodcentered6-22\textperiodcentered3) in the placebo group (HR 1\textperiodcentered11, 0\textperiodcentered83-1\textperiodcentered49, p=0\textperiodcentered48). Within the first 31 days of treatment, adverse events of grade 3 or worse were reported by 126 (14%) of 894 patients in the MAGE-A3 group and 56 (12%) of 450 patients in the placebo group, treatment-related adverse events of grade 3 or worse by 36 (4%) patients given MAGE-A3 vs six (1%) patients given placebo, and at least one serious adverse event by 14% of patients in both groups (129 patients given MAGE-A3 and 64 patients given placebo). The most common adverse events of grade 3 or worse were neoplasms (33 [4%] patients in the MAGE-A3 group vs 17 [4%] patients in the placebo group), general disorders and administration site conditions (25 [3%] for MAGE-A3 vs four [\textless1%] for placebo) and infections and infestations (17 [2%] for MAGE-A3 vs seven [2%] for placebo). No deaths were related to treatment. INTERPRETATION: An antigen-specific immunotherapeutic alone was not efficacious in this clinical setting. Based on these findings, development of the MAGE-A3 immunotherapeutic for use in melanoma has been stopped. FUNDING: GlaxoSmithKline Biologicals SA.

Mots clés: Risk Assessment; Chemotherapy; Adjuvant; Internationality; Melanoma; Skin Neoplasms; Immunoconjugates; Antigens; Neoplasm; Neoplasm Proteins; Injections; Intramuscular; Humans; Female; Male; Adult; Aged; Disease-Free Survival; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Survival Analysis; Treatment Outcome; Double-Blind Method; Prognosis; Immunotherapy

Domaines: Sciences du Vivant [q-bio]

Lev Demidov, John A. Thompson, Igor Bondarenko, Jaroslaw Jaroszek, Susana Puig, et al.. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, 2018, 19 (7), pp.916--929. ⟨10.1016/S1470-2045(18)30254-7⟩. ⟨hal-02320317⟩